Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy

The research evaluated the effects of oral Spironolactone (SPRL) on 103 patients with Central Serous Chorioretinopathy (CSC). It found that SPRL significantly improved central macular thickness, subretinal fluid (SRF) height, and subfoveal choroidal thickness at 1, 3, and 6 months after therapy. However, best-corrected visual acuity didn't significantly change. Complete resolution of SRF was higher in chronic CSC patients than in acute CSC patients at 1 month (21.1% vs. 6.0%). Recurrence occurred in 14 (13.1%) eyes after complete SRF resolution, with older age, more previous intravitreal bevacizumab injections, and poor initial visual acuity associated with recurrence. No permanent adverse effects were observed, but one patient experienced increased hair loss after 1 month of SPRL use. The study concluded that SPRL showed therapeutic benefits in CSC patients in terms of SRF resolution, but recurrence was relatively frequent, especially in older patients.